拟议生物类似药MSB11456与托珠单抗参照品在中重度类风湿关节炎受试者中的疗效与安全性比较:一项随机双盲研究结果
这项多中心随机双盲平行组研究纳入604例对至少一种改善病情抗风湿药反应不足且正在使用甲氨蝶呤的中重度活动性类风湿关节炎患者,比较MSB11456与欧盟批准的托珠单抗参照品每24周皮下注射162 mg的疗效、免疫原性和安全性。第24周时两组DAS28-ESR自基线变化的最小二乘均数差为0.01(95%CI -0.19至0.22),治疗等效性成立,其他疗效、安全性和免疫原性终点均显示相似性。
要点
- 第24周两组DAS28-ESR自基线变化的最小二乘均数差为0.01(95%CI -0.19至0.22),落在预设等效区间内。
- 所有其他疗效、安全性和免疫原性终点均显示两种治疗相似。
- 从欧盟批准托珠单抗转换为MSB11456的患者中也观察到相似性。
核心结论
- 疗效终点显示治疗等效性,安全性和免疫原性分析支持两种治疗相似。
- 研究结果强化了拟议生物类似药MSB11456与欧盟批准托珠单抗产生相似临床效应的证据。
研究设计与样本
- 多中心、随机、双盲、跨国、平行组研究(NCT04512001)。
- 纳入对至少一种改善病情抗风湿药(合成或生物制剂)临床反应不足且正在使用甲氨蝶呤的成人中重度活动性类风湿关节炎患者。
- 患者随机接受24次每周皮下注射162 mg的MSB11456或欧盟批准的托珠单抗。
- 第24周时患者再次随机接受继续治疗或MSB11456。
- 共604例随机患者。
主要发现
- 第24周时,两种治疗间DAS28-ESR自基线变化的最小二乘均数差为0.01(95%CI -0.19至0.22)。
- 所有其他疗效、安全性和免疫原性终点均显示两种治疗相似,包括从欧盟批准托珠单抗转换为MSB11456的患者。
关键数值与推荐
- 若两种治疗间DAS28-ESR自基线至第24周平均变化的95%CI(欧洲药品管理局)/90%CI(美国食品药品监督管理局)完全落在预设等效区间(分别为-0.6至0.6和-0.6至0.5)内,则认为治疗等效。
- 第24周时两种治疗间DAS28-ESR自基线变化的最小二乘均数差为0.01(95%CI -0.19至0.22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy, immunogenicity and safety of the proposed biosimilar MSB11456 versus European Union (EU)-approved tocilizumab reference product in patients with rheumatoid arthritis (RA) in a multicentre, randomised, double-blind, multinational, parallel-group study (NCT04512001). METHODS: Adult patients with moderate-to-severe active RA and inadequate clinical response to ≥1 disease-modifying antirheumatic drug (synthetic or biologic) receiving methotrexate were randomised to receive 24 weekly subcutaneous 162 mg injections of either MSB11456 or EU-approved tocilizumab. Equivalence between treatments was considered if the 95% CI (European Medicines Agency)/90% CI (US Food and Drug Administration) for the difference in mean change from baseline to week 24 in Disease Activity Score-28 Joint Count with erythrocyte sedimentation rate (DAS28-ESR) between treatments was entirely within prespecified equivalence intervals (-0.6 to 0.6 and -0.6 to 0.5, respectively). At week 24, patients were rerandomised to continued treatment or MSB11456. Secondary efficacy endpoints to week 52, and safety and immunogenicity to week 55 were also evaluated. RESULTS: At week 24, the least squares mean difference in the change from baseline in DAS28-ESR between treatments was 0.01 (95% CI -0.19 to 0.22) in the 604 randomised patients. Similarity between treatments was shown for all other efficacy, safety and immunogenicity endpoints, including in patients who switched from EU-approved tocilizumab to MSB114466. CONCLUSIONS: Therapeutic equivalence was demonstrated for efficacy endpoints, and safety and immunogenicity analyses support the similarity of the two treatments. The results of this study strengthen the evidence that the proposed biosimilar MSB11456 and EU-approved tocilizumab exert similar clinical effects.
引用
- Zubrzycka-Sienkiewicz A, Klama K, Ullmann M, et al. Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study. RMD Open. 2024. PMID: 38316489. doi:10.1136/rmdopen-2023-003596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。